Abstract
Objective To compare healthcare recourse utilizations (HCRU) and all-cause medical costs among individuals 50 years or older who received both influenza and COVID-19 vaccines on the same day and those that received influenza vaccine only
Methods We conducted a retrospective cohort study leveraging Optum’s de-identified Clinformatics® DataMart from 8/31/2021 to 7/31/2023. Individuals 50 years or older continuously enrolled in health plans for one year prior and until 7/31/2023 were included in the study. Subjects were categorized into 2 cohorts based on their vaccination status between 8/31/2022 and 1/31/2023: receiving influenza and COVID-19 vaccine on same day (co-admin cohort) and receiving influenza vaccine only (influenza cohort). The association between vaccination status and all-cause, influenza-related, COVID-related, pneumonia-related, and cardiorespiratory-related hospitalization, as well as outpatient or emergency room visits and all-cause medical costs was estimated by weighted generalized linear models, adjusting for confounding by stabilized inverse probability of treatment weighting.
Results 613,156 (mean age: 71) and 1,340,011 (mean age: 72) individuals were included in the co-admin and influenza cohort respectively. After weighting, the baseline characteristics were balanced between cohorts. The co-admin cohort was at statistically significant lower risk of all-cause (RR: 0.95, 95%CI: 0.93-0.96), COVID-19-related (RR: 0.59, 95%CI: 0.56-0.63), cardiorespiratory-related (RR: 0.94, 95%CI: 0.93-0.96) and pneumonia-related (RR: 0.86, 95%CI: 0.83-0.90) hospitalization but not influenza-related hospitalizations (RR: 0.91, 95%CI: 0.81, 1.04) compared to influenza cohort. Co-administration was associated with 3% lower all-cause medical cost (cost ratio: 0.974, 95% CI: 0.968, 0.979) during the follow-up period compared to receiving influenza vaccine only.
Conclusion Receiving both COVID-19 and influenza vaccines on the same day in comparison to receipt of influenza vaccine only was associated with reduced risk of HCRU, especially COVID-19 related hospitalization and all-cause medical costs. Interventions that increase vaccine coverage, particularly for COVID-19 might have public health and economic benefits.
Competing Interest Statement
All authors are employees of Moderna Inc. and might own stocks in the organization
Funding Statement
The study was funded by Moderna, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The analytical dataset used in the analyses would be made available at reasonable request.
